Towards a New Dawn for Neuro-Oncology: Nanomedicine at the Service of Drug Delivery for Primary and Secondary Brain Tumours DOI Creative Commons

Smita Khilar,

Antonina Dembinska-Kenner,

Helen Hall

et al.

Brain Sciences, Journal Year: 2025, Volume and Issue: 15(2), P. 136 - 136

Published: Jan. 30, 2025

(1) Background/Objectives: Primary and secondary brain tumours often hold devastating prognoses low survival rates despite the application of maximal neurosurgical resection, state-of-the-art radiotherapy chemotherapy. One limiting factor in their management is that several antineoplastic agents are unable to cross blood–brain barrier (BBB) reach tumour microenvironment. Nanomedicine could potential become an effective means drug delivery overcome previous hurdles towards neuro-oncological treatments. (2) Methods: A scoping review following PRISMA-ScR guidelines checklist was conducted using key terms input into PubMed find articles reflect emerging trends utilisation nanomedicine for primary tumours. (3) Results: The highlights various strategies by which different nanoparticles can be exploited bypass BBB; we provide a synthesis literature on ongoing contributions therapeutic protocols based chemotherapy, immunotherapy, focused ultrasound, radiotherapy/radiosurgery, radio-immunotherapy. (4) Conclusions: summarised this indicate encouraging advantageous properties as mechanisms; however, there still nanotoxicity issues largely remain addressed before translation these innovations from laboratory clinical practice.

Language: Английский

Towards a New Dawn for Neuro-Oncology: Nanomedicine at the Service of Drug Delivery for Primary and Secondary Brain Tumours DOI Creative Commons

Smita Khilar,

Antonina Dembinska-Kenner,

Helen Hall

et al.

Brain Sciences, Journal Year: 2025, Volume and Issue: 15(2), P. 136 - 136

Published: Jan. 30, 2025

(1) Background/Objectives: Primary and secondary brain tumours often hold devastating prognoses low survival rates despite the application of maximal neurosurgical resection, state-of-the-art radiotherapy chemotherapy. One limiting factor in their management is that several antineoplastic agents are unable to cross blood–brain barrier (BBB) reach tumour microenvironment. Nanomedicine could potential become an effective means drug delivery overcome previous hurdles towards neuro-oncological treatments. (2) Methods: A scoping review following PRISMA-ScR guidelines checklist was conducted using key terms input into PubMed find articles reflect emerging trends utilisation nanomedicine for primary tumours. (3) Results: The highlights various strategies by which different nanoparticles can be exploited bypass BBB; we provide a synthesis literature on ongoing contributions therapeutic protocols based chemotherapy, immunotherapy, focused ultrasound, radiotherapy/radiosurgery, radio-immunotherapy. (4) Conclusions: summarised this indicate encouraging advantageous properties as mechanisms; however, there still nanotoxicity issues largely remain addressed before translation these innovations from laboratory clinical practice.

Language: Английский

Citations

0